Clinical Pharmacokinetics of Phenobarbital

Slides:



Advertisements
Similar presentations
Clinical Pharmacokinetics Review Keith Christensen, Pharm D, BCPS Assistant Professor of Pharmacy Practice Pulmonary & Critical Care Medicine Creighton.
Advertisements

Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Pharmacokinetics Questions
Nonlinear pharmacokinetics
Dosage Regimen Design for Patients with Renal Insufficiency Pharmacy 732 Winter, 2001.
Multiple IV Dosing Pharmacokinetic Research, Bioequivalence Studies,
Dosage Adjustments for Aminoglycosides in Obese Patients Dennis Mungall, Pharm.D. Associate Professor, Pharmacy Practice Director, NTPD OSU,College of.
Laplace transformation
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Dose Adjustment in Renal and Hepatic Disease
Dosage Regimens II Arthur G. Roberts. Question Can a drug have a low therapeutic index and a broad therapeutic window? No therapeutic index= [drug] min,toxicity.
Dosing Regimen Design Infusion regimen.
Gokaraju Rangaraju College of Pharmacy
Module 2 # 3 Pharmacokinetics how to make sense of the previous lesson or why do I have to learn this stuff?
INTRAVENOUS INFUSION.
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
Nonlinear Pharmacokinetics
Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.
From A Physiologic Perspective Chemical Clearance from the Body
Clinical Pharmacokinetics of Lithium Dr. Muslim Suardi, MSi., Apt. School of Pharmacy, Faculty of Science University of Andalas 2004.
Intravenous Infusion Previous rates of administration were instantaneous IV bolus and first order absorption. As a rate (mg/hr) a first order rate constantly.
Multiple dosing: intravenous bolus administration
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Calculation of Doses Prof. Dr. Henny Lucida, Apt.
Clinical Pharmacokinetics of Carbamazepine
PHARMACOKINETICS INTRODUCTION
Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration.
Continuous intravenous infusion (one-compartment model)
INTRODUCTION CLINICAL PHARMACOKINETICS
Prof. Dr. Henny Lucida, Apt
Clinical Pharmacokinetics of Aminoglycosides
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy, University of Andalas.
Clinical Pharmacokinetics of Procainamide Dr. Muslim Suardi Faculty of Pharmacy University of Andalas 2013.
INTERMITTENT IV VANCOMYCIN WHAT DOSE SHOULD WE START WITH?
Carbamazepine (Tegretol) Carbamazepine is one of the older drugs used for the treatment of epilepsy. It has a long history of effectiveness & safety. It.
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Clinical Pharmacokinetic Equations and Calculations
Lecture 2 Clearance, maintenance dose and AUC
The General Concepts of Pharmacokinetics and Pharmacodynamics
Learning objectives To know what data is available from pharmacokinetic studies in man and how to handle it To know how to calculate the basic pharmacokinetic.
Pharmacokinetic Questions
Quinidine Quinidine  It is used for atrial fibrillation & other arrhythmias. It is given orally as sulfate, gluconate or polygalacturonate salts & in.
Pharmacokinetics 3rd Lecture
VANCO Dr. Muslim Suardi Faculty of Pharmacy University of Andalas 2013.
1 Vancomycin Pharmacokinetics. 2 Introduction Vancomycin is a glycopeptide antibiotic Mechanism of Action –Exhibits a time dependent or concentration-
Allie punke Pharmacokinetics tutoring Fall 2016
Anticonvulsants: Phenytoin
Allie punke Pharmacokinetics tutoring Fall 2016
Vancomycin administered by continuous infusion should be dosed according to clearance and not based on the patient's body weight P. M. Tulkens1, P. Wallemacq1.
Clinical Pharmacokinetics of VANCOMYCIN
The aminoglycoside antibiotics
Pharmacokinetics Tutoring
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics.
PHARMACOKINETICS Allie punke
Cyclosporine.
Pharmacokinetics Tutoring
29 Vancomycin Administered by Continuous Infusion
Pharmacokinetics.
Anticonvulsants: Valproic acid
Pharmacokinetics: Theophylline
PHARMACOKINETICS Allie punke
Assist. Prof. Dr. Kadhim Ali Kadhim Ph.D, in Clinical Pharmacy
Clinical Pharmacokinetics
considering further dose(s)
Multiple ORAL Dosing Objectives
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Clinical Pharmacokinetics of Phenobarbital Dr. Muslim Suardi Faculty of Pharmacy University of Andalas 2013

INITIAL DOSAGE DETERMINATION METHODS Pharmacokinetic Dosing Method

Pharmacokinetic Dosing Method Estimation of Cl Vd t1/2 & ke

Problem GO is a 50-year-old, 75-kg (5 ft 10 in) male with tonic-clonic seizures who requires therapy with oral PHENO. He has normal liver and renal function. Suggest an initial PHENO dosage regimen designed to achieve a steady-state concentration equal to 20 µg/mL.

1. Estimate Cl & Vd according to disease states present in the patient. The Cl for an older patient is 4 mL/h/kg. Using this value, the estimated Cl would equal 0.3 L/h: Cl = 75 kg*4 mL/h/kg = 300 mL/h or 0.3 L/h. The estimated Vd would be 53 L: 75 kg*0.7 L/kg = 53 L.  

2. Estimate t1/2 & ke Once the correct Cl & Vd estimates are identified for the patient, they can be converted into the PHENO t1/2 & ke estimates using the following eq: t1/2 = (0.693*V)/Cl = (0.693*53L)/ 0.3 L/h = 122 h, k = Cl/V = 0.3 L/h / 53 L = 0.0057 h−1.

3. Compute Dosage Regimen Oral PHENO tab will be prescribed to this patient (F=1). The dosage equation for oral PHENO is D = (Css*Cl *) / F = (20 mg/L*0.3 L/h*24h) / 1 = 144 mg Rounded to 120 every 24h

3. Continued A SS trough PHENO Csr should be measured after SS is attained in 3–5 t1/2. Since the patient is expected to have a t1/2 equal to 122h, the PHENO Css could be obtained any time after 4 weeks of dosing (5t1/2= 5*122h = 610 h or 25 d).

3. Continued PHENO Csr should also be measured if the patient experiences an exacerbation of their epilepsy, or if the patient develops potential signs of PHENO toxicity. 3. Compute dosage regimen.

3. Continued Oral PHENO tablets will be prescribed to this patient (F=1). The dosage eq for oral PHENO is D = (Css ⋅ Cl ⋅) / F = (20 mg/L*0.3 L/h*24 h) / 1 = 144 mg, rounded to 120 every 24 hours. A SS trough PHENO Csr should be measured after SS is attained in 3–5t1/2.

3. Continued Since the patient is expected to have a half-life equal to 122h, the PHENO Css could be obtained any time after 4 weeks of dosing (5t1/2 = 5*122h = 610 h or 25 d). PHENO Csr should also be measured if the patient experiences an exacerbation of their epilepsy, or if the patient develops potential signs of PHENO toxicity.